🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Shanxi Bethune Hospital clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Shanxi Bethune Hospital as lead sponsor. Synced 26 Sep 2026
15Current trials
14Recruiting now
9Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Shanxi Bethune Hospital is the lead sponsor of 15 current clinical trials in our China register. 14 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Aclacinomycin, Aztreonam and Ceftazidime-avibactam. The most-studied condition is Autoimmune Diseases.

ClinicalTrials.gov trials by status

  • Recruiting1493%
  • Not yet open17%

Trials by phase

  • Not applicable747%
  • Observational427%
  • Phase EARLY_PHASE117%
  • Phase 317%
  • Phase 2/317%
  • Phase 217%
01

Clinical trials sponsored by Shanxi Bethune Hospital

15 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Intraosseous Infusion in Hematologic Critical Patients
NCT07239375 · ClinicalTrials.gov ↗ · Intraosseous Infusions
Observational Recruiting 2025-11 China
Integrated TCM - Western Medicine Strategy for Long - Distance Diabetes Management
NCT07265037 · ClinicalTrials.gov ↗ · Diabetes Mellitus, Type 2, Integrated Traditional Chinese Medicine and Western Medicine, Telemedicine
Not applicable Recruiting 2025-11 China
A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors
NCT06783816 · ClinicalTrials.gov ↗ · Acute Lymphocytic Leukemia, Lymphoma,Non-Hodgkin, Relapsed Refractory Multiple Myeloma
Not applicable Recruiting 2023-12 China
Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia
NCT05726110 · ClinicalTrials.gov ↗ · Relapsed or Refractory Acute Myeloid Leukemia
Phase 3 Recruiting 2023-01 China
Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL
NCT07059156 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, Adult
Phase 2/3 Recruiting 2025-06 China
Hybrid Closed-Loop in Diabetes Post-Kidney Transplant: A Randomized Trial
NCT06962410 · ClinicalTrials.gov ↗ · Diabetes Mellitus Patients With Kidney Transplantation
Not applicable Recruiting 2025-04 China
Umbilical Cord Blood-Supported Haplo-HSCT for Aplastic Anemia Treatment Study
NCT06650553 · ClinicalTrials.gov ↗ · Aplastic Anemias
Not applicable Recruiting 2024-06 China
Efficacy of Empirical Anti-Infective Therapy in Neutropenic Febrile Patients.
NCT07204522 · ClinicalTrials.gov ↗ · Febrile Neutropenia
Observational Recruiting 2025-09 China
Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma
NCT07497165 · ClinicalTrials.gov ↗ · Relapsed/Refractory Multiple Myeloma (RRMM), Multiple Myeloma
Observational Recruiting 2025-11 China
Efficacy of Integrated Induction-Consolidation Chemotherapy and Transplantation for Adult Acute Myeloid Leukemia: Multicenter Study
NCT07108530 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia
Phase 2 Recruiting 2025-08 China
Predicting Response to Selinexor-Based Therapy in Relapsed/Refractory Multiple Myeloma: A Multicenter Prospective Study
NCT07514052 · ClinicalTrials.gov ↗ · Multiple Myeloma of Bone
Observational Recruiting 2026-01 China
Hybrid Closed-Loop System in Neurosurgical Perioperative Hyperglycemia: An Open RCT
NCT06909071 · ClinicalTrials.gov ↗ · T2DM Patients With Traumatic Brain Injury
Not applicable Recruiting 2025-04 China
Hybrid Closed-Loop System in LADA Patients: A Randomized Trial
NCT06941675 · ClinicalTrials.gov ↗ · Latent Autoimmune Diabetes in Adults (LADA)
Not applicable Recruiting 2025-04 China
CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma
NCT06850285 · ClinicalTrials.gov ↗ · Lymphoma, B-Cell
Not applicable Recruiting 2025-09 China
JY231(Internal Clinical Drug Code) Injection for the Treatment of Refractory Autoimmune Diseases
NCT06243159 · Autoimmune Diseases
Phase EARLY_PHASE1 Not yet open 2024-02 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Shanxi Bethune Hospital trials

9 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Shanxi Bethune Hospital trials

21 conditions
Autoimmune Diseases1Intraosseous Infusions1Diabetes Mellitus, Type 21Integrated Traditional Chinese Medicine and Western Medicine1Telemedicine1Chronic Disease Management1Acute Lymphocytic Leukemia1Lymphoma,Non-Hodgkin1Relapsed Refractory Multiple Myeloma1Relapsed or Refractory Acute Myeloid Leukemia1Acute Lymphoblastic Leukemia, Adult1Diabetes Mellitus Patients With Kidney Transplantation1Aplastic Anemias1Febrile Neutropenia1Relapsed/Refractory Multiple Myeloma (RRMM)1Multiple Myeloma1Acute Myeloid Leukemia1Multiple Myeloma of Bone1T2DM Patients With Traumatic Brain Injury1Latent Autoimmune Diabetes in Adults (LADA)1Lymphoma, B-Cell1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China1514

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Autoimmune Diseases

SponsorTrials
The Children's Hospital of Zhejiang University School of Medicine6
Essen Biotech2
Adicet Therapeutics1
The First Affiliated Hospital of University of Science and Technology of China1
YANRU WANG1

Sponsors with the most current trials registered for this condition.

06

Questions about Shanxi Bethune Hospital trials

How many clinical trials does Shanxi Bethune Hospital sponsor?

Shanxi Bethune Hospital is the lead sponsor of 15 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Shanxi Bethune Hospital trials recruiting?

Yes. 14 of its 15 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Shanxi Bethune Hospital testing?

Its current trials name 9 drugs and biologicals as interventions. The most frequent are Aclacinomycin (1), Aztreonam (1), Ceftazidime-avibactam (1), Cytarabine (1) and Daunorubicin (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.